Navigation Links
Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
Date:2/14/2008

(NSCLC) patients who have tumor progression after having previously

benefited from EGFR inhibitors.

-- Presented comprehensive phase 1 data for XL880 in June, and published

abstracts on phase 1 data for XL184, XL647 and XL880.

-- Reported phase 2 proof-of-concept data for XL647 as first-line therapy

for NSCLC in September.

-- Presented phase 1 data for second-generation MET inhibitor XL184,

selective PI3K inhibitor XL147 and dual PI3K/mTOR inhibitor XL765, and

phase 2 data for XL880 in papillary renal cell carcinoma and phase 2

data for XL647 in NSCLC in October.

-- Presented encouraging phase 1 data for XL019, our selective inhibitor

of JAK2, in December.

-- Filed investigational new drug applications for four compounds: XL418

(January), XL147 (March), XL765 (April) and XL019 (May).

-- Advanced new development candidates into preclinical development,

including XL139 (Hedgehog antagonist), XL888 (HSP90 inhibitor) and

XL652 (LXR modulator).

-- Held our Third Annual Exelixis Research and Development Day in

December.

Business Development

-- Retained rights to develop and commercialize XL647 after

GlaxoSmithKline declined to exercise its option to further develop and

commercialize the compound.

-- Received notice of GlaxoSmithKline's selection of XL880 for further

development and commercialization. We expect the XL880 program to be

transferred to GlaxoSmithKline in the first quarter of 2008.

-- Presented phase 2 data for XL784 in November indicating that XL784 did

not meet its primary endpoint, and as expected, GSK chose not to

exercise its option to further develop XL784. Based on encouraging

data from a subgroup analysis, the compound may nevertheless have

potential to benefit patients with diabet
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
4. Exelixis Announces Senior Management Promotions
5. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
6. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
7. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
8. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
11. Exelixis Sells 80% Stake in Artemis to Taconic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... March 18 InterMune, Inc.,(Nasdaq: ITMN ) ... former employee in connection with the promotional activities ... in June of,2003., "Today,s indictment concerns conduct ... than four years ago., "In 2006, InterMune ...
... HOPKINTON, Mass., March 18 Caliper Life,Sciences, Inc. ... presentation at the,Lehman Brothers Global Healthcare Conference in ... 5:15 p.m. EDT. Kevin Hrusovsky, President and CEO ... company,s business. The live,webcast can be accessed at, ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... it will,report results for its fourth quarter and year-end ... A conference call to review the results will ... 26, 2008 and will be hosted by Anthony DiTonno,President ...
Cached Biology Technology:Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct 2Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct 3NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 2NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 3
(Date:7/11/2014)... new professorship in tissue engineering to promote innovative ... and the Marine Biological Laboratory, supported by a ... Bell Foundation., The Eugene Bell Professorship in Tissue ... Engineering. That endowed chair holder also will direct ... Center for Regenerative Biology and Tissue Engineering, and ...
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2Molecular snapshots of oxygen formation in photosynthesis 2
... caused by bisphenol A (BPA) presence in reusable plastic ... made with supposed BPA-free materials. Prompted by requests ... wanted to see if these alternativesincluding products made with ... an option free of BPA. In a study ...
... Fla. (July. 11, 2011) A study published ... (20:5) investigating optimal routes for transplanting neural stem/progenitor cells ... has demonstrated that intralesional (IL) injection conferred benefits over ... study, by a team of Keio University (Japan) researchers, ...
... contribution to marine science and a superb way of ... into a format and language that can only enhance ... senior vice president for marine conservation and chief scientist ... climate, nurture marine ecosystems full of aquatic life, and ...
Cached Biology News:Research shows 'BPA-free' bottles live up to manufacturers' claims 2Research shows 'BPA-free' bottles live up to manufacturers' claims 3Neural stem progenitor cell transplantation’s potential to aid spinal cord injury tested 2
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 5,000 units polymerase, ...
... the formation of a phosphodiester bonds between ... duplex DNA molecules or between oligonucleotides which ... at 45 - 65?. Tfi DNA Ligase ... temperatures than conventional DNA ligases, Thus, Tfi ...
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and ... royalties for your hard work and endeavour! ... build it up,and market it internationally. We ...
Biology Products: